The Functions of IFITM Proteins in Control of Influenza A Virus Infection

性状（由申请方提供）：甲型流感病毒（IAV）是一种重要的病原体。在美国，每年有20万人住院治疗，4.1万人死亡。我们以前的研究表明，干扰素诱导跨膜蛋白（IFITM）是体外和体内免疫控制IAV的关键因素。我们证明，在已知的病毒限制因子中，IFITM蛋白在病毒进入细胞之前限制病毒。我们的总体目标是全面了解IFITM蛋白的功能和这些蛋白限制IAV感染的机制。这些研究包括三个具体目标。目标1。我们将确定IFITM 3多态性的稳定性是否有助于它们对IAV的差异控制。我们已经证明，IFITM 3的表达密切调节分泌载体膜蛋白3（SCAMP 3）。我们还注意到最近鉴定的多态性IFITM 3（21 IFITM 3）的稳定性可以解释其与不良临床预后的相关性。为此，将进行一系列免疫沉淀、免疫印迹、药物抑制和病毒进入测定以确定促成IFITM 3降解的途径和SCAMP 3稳定其表达的机制。我们还将研究SCAMP 3在野生型IFITM 3和21 IFITM 3对IAV的差异控制中的作用。目标二。我们将研究IFITM蛋白是否改变细胞内胆固醇稳态，导致病毒进入限制。在我们的初步研究中，我们观察到IFITM 3通过与囊泡相关膜蛋白相关蛋白A（VAPA）的相互作用干扰细胞内胆固醇的稳态。在这个目标中，我们将澄清IFITM介导的胆固醇积累是否有助于病毒进入限制。为此，我们将全面表征野生型和功能性阴性IFITM 3变体的特性及其在正常或胆固醇耗尽条件下对病毒进入的影响。我们还将评估这种胆固醇积累是否可以类似地由IFN诱导。最后，通过共聚焦成像确定胆固醇积累对病毒体和细胞膜之间融合的影响。目标3。我们将研究IFITM蛋白是否干扰内吞作用的后期阶段，从而阻断病毒粒子运输的进展。由于IFITM 3也与几种囊泡运输相关蛋白如CD 63相互作用，因此内体运输的改变是IFITM介导的限制的另一种潜在机制。在这个目标中，我们将进行活细胞成像和无细胞细胞器融合试验，以检查IFITM蛋白是否干扰内吞作用的后期阶段。IFITM 3对内体磷脂酰肌醇的组成以及对CD 63和几种对内体运输至关重要的细胞因子（例如，磷脂酰肌醇4-激酶（PI 4K）和衔接蛋白3（AP-3））也将通过共聚焦显微镜和生物化学分析来表征。我们将进一步评估PI 4K、AP-3和CD 63是否改变IFITM介导的病毒进入限制。

DESCRIPTION (provided by applicant): Influenza A virus (IAV) is an important pathogen. It is responsible for 200,000 hospitalizations and 41,000 deaths in the United States annually. Our previous studies identified that interferon-inducible transmembrane (IFITM) proteins are critical factors for the immune control of IAV in vitro and in vivo. We demonstrated that, uniquely among known viral restriction factors, IFITM proteins restricted viruses before they entered cells. Our overall goal of this proposed project is to understand comprehensively the functions of IFITM proteins and the mechanisms by which these proteins restrict IAV infection. These studies consist of three specific aims. Aim 1. We will determine whether the stability of IFITM3 polymorphisms contribute to their differential control of IAV. We have demonstrated that IFITM3 expression is closely regulated by secretory carrier membrane protein 3 (SCAMP3). We have also noticed that the stability of a recently identified polymorphic IFITM3 ( 21 IFITM3) may explain its correlation to the poor clinical prognosis. In this aim, a series of immunoprecipitatio, immunoblotting, drug inhibitory, and viral entry assays will be performed to determine the pathway contributing to IFITM3 degradation and the mechanism by which SCAMP3 stabilizes its expression. We will also investigate the role of SCAMP3 in the differential control of IAV by wild-type IFITM3 and 21 IFITM3. Aim 2. We will investigate whether IFITM proteins alter intracellular cholesterol homeostasis, resulting in viral entry restriction. In our preliminary studies, we observed that IFITM3 interferes with the homeostasis of intracellular cholesterol via its interaction with vesicle-associated membrane protein-associated protein A (VAPA). In this aim we will clarify whether IFITM-mediated cholesterol accumulation contributes to viral entry restriction. To do so, we will comprehensively characterize the properties of wild-type and functional negative IFITM3 variants and their effects on viral entry under a normal or a cholesterol-depleted condition. We will also evaluate whether this cholesterol accumulation can be similarly induced by IFN. Finally, the effects of cholesterol accumulation on fusion between virion and cell membranes will be determined by confocal imaging. Aim 3. We will examine whether IFITM proteins interfere with the late stage of endocytosis, thereby blocking the progression of virion trafficking. Because IFITM3 also interacts with several vesicle trafficking-related proteins such as CD63, alteration of endosomal trafficking is another potential mechanism of IFITM-mediated restriction. In the aim, we will perform live-cell imaging and cell-free organelle fusion assays to examine whether IFITM proteins interfere with the late stage of endocytosis. The effects of IFITM3 on the composition of endosomal phosphatidylinositol and on the interactions between CD63 and several cellular factors critical for endosomal trafficking (e.g., phosphatidylinositol 4-kinases (PI4K) and adaptor protein 3 (AP-3)) will also be characterized by confocal microscopy and biochemical analyses. We will further evaluate whether PI4K, AP-3, and CD63 alter IFITM- mediated viral entry restriction.